GlassScriptPhysician profile
Julian Lee
NPI 1386803633
$7,113.13
in general payments reported to CMS, 2019-2025
56 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,821 · 2020: $456 · 2021: $76.30 · 2022: $79.88 · 2023: $843 · 2024: $1,704 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,605 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,604.82 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $982.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $824.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $477.13 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $444.31 | 2019-2025 | Rexulti |
| Abbvie INC. | $367.08 | 2021-2025 | |
| Lilly USA, LLC | $315.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $307.81 | 2024-2025 | Xyosted |
| Amgen INC. | $218.76 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.54 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $199.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $192.02 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $155.59 | 2019-2025 | |
| Dexcom, INC. | $152.16 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $134.01 | 2025 | Korlym |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.